PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
7796138-1	1995	alpha 2A-Adrenergic receptor (AR) and non-adrenergic imidazoline receptor (I-R) binding sites have been previously characterized in rat cerebral cortex membranes using the N-substituted oxazoline, [3H]rilmenidine ([3H]Ril) [King, P.R.	Rilmenidine	201-212	adrenoceptor alpha 2A	Rattus norvegicus	0-28
8703663-9	1995	During bicycle exercise, the increase in HR was significantly greater after rilmenidine (+50 vs 41 beats min-1, P = 0.04).	Rilmenidine	76-87	CD59 molecule (CD59 blood group)	Homo sapiens	105-110
7643129-5	1995	Other putative imidazoline receptor agonists, including cimetidine, rilmenidine, and imidazole-4-acetic acid, likewise enhance PNMT mRNA production showing relative potencies that correlate with their binding affinities at chromaffin cell I1-imidazoline binding sites.	Rilmenidine	68-79	phenylethanolamine-N-methyltransferase	Rattus norvegicus	127-131
8872295-5	1996	However, because only activation of the alpha(2)-adrenergic receptors appears responsible for somnolence, the imidazoline-receptor agonists moxonidine and rilmenidine, both relatively selective for I-receptors, may have superior clinical utility in antihypertensive therapy, since they are sympatholytic and also suppress the generation of angiotensin II.	Rilmenidine	155-166	angiotensinogen	Homo sapiens	340-354
8521919-2	1995	In contrast, the oxazoline [3H]rilmenidine labelled a high density of non-adrenergic sites in the cortex and outer stripe of the outer medulla, a lower density in the inner stripe and inner medulla and a low density of alpha 2A-adrenoceptor sites in inner medulla.	Rilmenidine	31-42	adrenoceptor alpha 2A	Rattus norvegicus	219-240
7477880-0	1995	Clonidine and rilmenidine suppress hypotension-induced Fos expression in the lower brainstem of the conscious rabbit.	Rilmenidine	14-25	proto-oncogene c-Fos	Oryctolagus cuniculus	55-58
7477880-12	1995	Rilmenidine pretreatment also greatly reduced Fos expression in the lower brainstem, with a very similar pattern to that observed after clonidine pretreatment.	Rilmenidine	0-11	proto-oncogene c-Fos	Oryctolagus cuniculus	46-49
7998580-12	1994	The increase in free water clearance seen with the high dose of rilmenidine suggests that the inhibitory effect of alpha 2-adrenoceptor activation on vasopressin is involved at this dose.	Rilmenidine	64-75	arginine vasopressin	Rattus norvegicus	150-161
1832761-5	1991	Both groups were similar at randomisation, and both treatments were similarly effective: after 8 weeks of monotherapy with rilmenidine or atenolol, the SBP/DBP had decreased by -18/-13 mmHg and by -21/-15 mmHg respectively, and the proportion of patients with normalised blood pressure (SBP/DBP less than or equal to 160/90 mmHg) was 66 percent and 65 percent.	Rilmenidine	123-134	selenium binding protein 1	Homo sapiens	152-155
1376817-8	1992	Thus, an inhibitory interaction between rilmenidine and NPY was observed at the hemodynamic and second-messenger level in the SHR.	Rilmenidine	40-51	neuropeptide Y	Rattus norvegicus	56-59
1832761-5	1991	Both groups were similar at randomisation, and both treatments were similarly effective: after 8 weeks of monotherapy with rilmenidine or atenolol, the SBP/DBP had decreased by -18/-13 mmHg and by -21/-15 mmHg respectively, and the proportion of patients with normalised blood pressure (SBP/DBP less than or equal to 160/90 mmHg) was 66 percent and 65 percent.	Rilmenidine	123-134	D-box binding PAR bZIP transcription factor	Homo sapiens	156-159
1832761-5	1991	Both groups were similar at randomisation, and both treatments were similarly effective: after 8 weeks of monotherapy with rilmenidine or atenolol, the SBP/DBP had decreased by -18/-13 mmHg and by -21/-15 mmHg respectively, and the proportion of patients with normalised blood pressure (SBP/DBP less than or equal to 160/90 mmHg) was 66 percent and 65 percent.	Rilmenidine	123-134	selenium binding protein 1	Homo sapiens	287-290
1832761-5	1991	Both groups were similar at randomisation, and both treatments were similarly effective: after 8 weeks of monotherapy with rilmenidine or atenolol, the SBP/DBP had decreased by -18/-13 mmHg and by -21/-15 mmHg respectively, and the proportion of patients with normalised blood pressure (SBP/DBP less than or equal to 160/90 mmHg) was 66 percent and 65 percent.	Rilmenidine	123-134	D-box binding PAR bZIP transcription factor	Homo sapiens	291-294
26598394-2	2016	We demonstrated that the antihypertensive drug rilmenidine, a selective imidazoline I1 receptor agonist, modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells.	Rilmenidine	47-58	BCL2 associated X, apoptosis regulator	Homo sapiens	169-172
2782324-9	1989	In conclusion, rilmenidine offers an effective and safe treatment for mild-to-moderate hypertension in diabetic patients treated with insulin and does not interfere with their blood glucose control.	Rilmenidine	15-26	insulin	Homo sapiens	134-141
31158332-5	2019	Reduction of Ca2+-currents by rilmenidine, a specific agonist of I1R, ensued from the phosphatidylcholine-specific phospholipase C-mediated activation of protein kinase C. There is a stimulation of serine/threonine phosphatase activity.	Rilmenidine	30-41	nischarin	Rattus norvegicus	65-68
28980850-0	2018	Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression.	Rilmenidine	0-11	mechanistic target of rapamycin kinase	Mus musculus	21-25
28980850-0	2018	Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression.	Rilmenidine	0-11	superoxide dismutase 1, soluble	Mus musculus	62-66
28980850-6	2018	Treatment of these cells with rilmenidine, an anti-hypertensive agent and imidazoline-1 receptor agonist that induces autophagy, promoted autophagic clearance of mutant SOD1 and efficient mitophagy.	Rilmenidine	30-41	nischarin	Mus musculus	74-96
28980850-6	2018	Treatment of these cells with rilmenidine, an anti-hypertensive agent and imidazoline-1 receptor agonist that induces autophagy, promoted autophagic clearance of mutant SOD1 and efficient mitophagy.	Rilmenidine	30-41	superoxide dismutase 1, soluble	Mus musculus	169-173
28980850-7	2018	Rilmenidine administration to mutant SOD1G93A mice upregulated autophagy and mitophagy in spinal cord, leading to reduced soluble mutant SOD1 levels.	Rilmenidine	0-11	superoxide dismutase 1, soluble	Mus musculus	37-41
28980850-7	2018	Rilmenidine administration to mutant SOD1G93A mice upregulated autophagy and mitophagy in spinal cord, leading to reduced soluble mutant SOD1 levels.	Rilmenidine	0-11	superoxide dismutase 1, soluble	Mus musculus	137-141
28980850-8	2018	Importantly, rilmenidine increased autophagosome abundance in motor neurons of SOD1G93A mice, suggesting a direct action on target cells.	Rilmenidine	13-24	superoxide dismutase 1, soluble	Mus musculus	79-83
28980850-9	2018	Despite robust induction of autophagy in vivo, rilmenidine worsened motor neuron degeneration and symptom progression in SOD1G93A mice.	Rilmenidine	47-58	superoxide dismutase 1, soluble	Mus musculus	121-125
28980850-10	2018	These effects were associated with increased accumulation and aggregation of insoluble and misfolded SOD1 species outside the autophagy pathway, and severe mitochondrial depletion in motor neurons of rilmenidine-treated mice.	Rilmenidine	200-211	superoxide dismutase 1, soluble	Mus musculus	101-105
33798740-0	2021	Stimulation of mTOR-independent autophagy and mitophagy by rilmenidine exacerbates the phenotype of transgenic TDP-43 mice.	Rilmenidine	59-70	mechanistic target of rapamycin kinase	Mus musculus	15-19
33798740-0	2021	Stimulation of mTOR-independent autophagy and mitophagy by rilmenidine exacerbates the phenotype of transgenic TDP-43 mice.	Rilmenidine	59-70	TAR DNA binding protein	Mus musculus	111-117
33798740-5	2021	The clinically approved anti-hypertensive drug rilmenidine was used to stimulate mTOR-independent autophagy in double transgenic TDP-43WTxQ331K mice to alleviate impaired autophagy.	Rilmenidine	47-58	mechanistic target of rapamycin kinase	Mus musculus	81-85
33798740-6	2021	Although rilmenidine treatment induced robust autophagy in spinal cords, this exacerbated the phenotype of TDP-43WTxQ331K mice shown by truncated lifespan, accelerated motor neuron loss and pronounced nuclear TDP-43 clearance.	Rilmenidine	9-20	TAR DNA binding protein	Mus musculus	107-113
33798740-6	2021	Although rilmenidine treatment induced robust autophagy in spinal cords, this exacerbated the phenotype of TDP-43WTxQ331K mice shown by truncated lifespan, accelerated motor neuron loss and pronounced nuclear TDP-43 clearance.	Rilmenidine	9-20	TAR DNA binding protein	Mus musculus	209-215
33798740-7	2021	Importantly, rilmenidine significantly promoted mitophagy in spinal cords TDP-43WTxQ331K mice, evidenced by reduced mitochondrial markers and load in spinal motor neurons.	Rilmenidine	13-24	TAR DNA binding protein	Mus musculus	74-80
34298888-6	2021	Interestingly, in cultured neuroblastoma cells, we found that the mammalian target of rapamycin-independent autophagy activators, lithium chloride and rilmenidine, rescued these cells against proteasome inhibition-induced death.	Rilmenidine	151-162	mechanistic target of rapamycin kinase	Homo sapiens	66-95
2570851-1	1989	Studies were carried out to determine whether rilmenidine, a recently introduced antihypertensive agent with a similar mechanism of action of clonidine, possesses histamine-like activity on tissues responding to histamine H2-receptor agonists.	Rilmenidine	46-57	histamine receptor H 2	Rattus norvegicus	212-233
2570851-2	1989	In guinea-pig isolated atria, both histamine and clonidine caused concentration-dependent positive chronotropic effects which were blocked by the histamine H2-receptor antagonist cimetidine (5 microM); in contrast, rilmenidine produced a concentration-dependent negative chronotropic effect which was not altered by cimetidine.	Rilmenidine	215-226	histamine H2 receptor	Cavia porcellus	146-167
27086551-6	2016	These effects were accompanied by a reversal of functional and structural capillary rarefaction in the skeletal muscle in both treated groups and an increase in SCD in the left ventricle only in the rilmenidine group.	Rilmenidine	199-210	stearoyl-CoA desaturase	Rattus norvegicus	161-164
26598394-3	2016	Rilmenidine acts through a mechanism which involves deactivation of Ras/MAP kinases ERK, p38 and JNK.	Rilmenidine	0-11	mitogen-activated protein kinase 14	Homo sapiens	89-92
26598394-3	2016	Rilmenidine acts through a mechanism which involves deactivation of Ras/MAP kinases ERK, p38 and JNK.	Rilmenidine	0-11	mitogen-activated protein kinase 8	Homo sapiens	97-100
23430592-4	2013	At first, an intracerebroventricular (ICV) injection of anti-NISCH antibody blocked the blood pressure lowering action of rilmenidine (I-1 receptor agonist) in spontaneous hypertensive rat (SHR).	Rilmenidine	122-133	nischarin	Rattus norvegicus	61-66
23516130-4	2013	Chronic administration of rilmenidine into HFD-fed mice for 8 weeks significantly reduced body weight, which was reversed by efaroxan at the dose sufficient to block I1R.	Rilmenidine	26-37	nischarin	Mus musculus	166-169
23516130-8	2013	In addition, epididymal white adipose tissue (eWAT) cell size in HFD-fed mice was decreased by rilmenidine via the activation of I1R.	Rilmenidine	95-106	nischarin	Mus musculus	129-132
23516130-10	2013	Taken together, we suggest that rilmenidine can improve obesity in HFD-fed mice through an activation of I1R to ameliorate energy intake and eWAT accumulation.	Rilmenidine	32-43	nischarin	Mus musculus	105-108
20816810-11	2010	The present results demonstrated that pertussis toxin-sensitive G protein, phosphatidylinositol 3-kinase-Akt-GSK3beta signaling pathway and endogenous nitric oxide may play a key role in antiarrhythmic effect of centrally administered rilmenidine.	Rilmenidine	235-246	glycogen synthase kinase 3 beta	Rattus norvegicus	109-117
22674473-1	2012	Imidazoline I1-receptors (I1R) are known to regulate blood pressure and rilmenidine, an agonist, is widely used as antihypertensive agent in clinic.	Rilmenidine	72-83	nischarin	Mus musculus	26-29
22674473-9	2012	Moreover, the hypothalamic neuropeptide Y (NPY) level was reduced by rilmenidine that was also reversed by pretreatment with efaroxan.	Rilmenidine	69-80	neuropeptide Y	Mus musculus	27-41
22674473-9	2012	Moreover, the hypothalamic neuropeptide Y (NPY) level was reduced by rilmenidine that was also reversed by pretreatment with efaroxan.	Rilmenidine	69-80	neuropeptide Y	Mus musculus	43-46
22674473-10	2012	In conclusion, the obtained results suggest that rilmenidine can decrease food intake in STZ-diabetic mice through an activation of I1R to lower hypothalamic NPY level.	Rilmenidine	49-60	nischarin	Mus musculus	132-135
22674473-10	2012	In conclusion, the obtained results suggest that rilmenidine can decrease food intake in STZ-diabetic mice through an activation of I1R to lower hypothalamic NPY level.	Rilmenidine	49-60	neuropeptide Y	Mus musculus	158-161
20816810-0	2010	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway and endogenous nitric oxide are needed for the antiarrhythmic effect of centrally administered rilmenidine.	Rilmenidine	161-172	AKT serine/threonine kinase 1	Rattus norvegicus	44-47
20816810-4	2010	The present study was designed to examine a role of pertussis toxin-sensitive G protein, phosphatidylinositol 3-kinase/Akt signaling pathway and endogenous nitric oxide in the antiarrhythmic effect of rilmenidine.	Rilmenidine	201-212	AKT serine/threonine kinase 1	Rattus norvegicus	119-122
20816810-8	2010	We also performed Western blot analysis to determine phosphorylation of Akt and glycogen synthase kinase 3beta, a direct Akt downstream target, following the central administration of rilmenidine.	Rilmenidine	184-195	AKT serine/threonine kinase 1	Rattus norvegicus	72-75
23499689-4	2013	Clonidine, moxonidine and rilmenidine inhibited the EFS-induced gastric contractions in a concentration dependent manner in WT, alpha2B- and alpha2C-adrenoceptor KO mice, whereas they had no or only weak effect in alpha2A-adrenoceptor KO mice.	Rilmenidine	26-37	adrenergic receptor, alpha 2b	Mus musculus	128-135
23499689-4	2013	Clonidine, moxonidine and rilmenidine inhibited the EFS-induced gastric contractions in a concentration dependent manner in WT, alpha2B- and alpha2C-adrenoceptor KO mice, whereas they had no or only weak effect in alpha2A-adrenoceptor KO mice.	Rilmenidine	26-37	adrenergic receptor, alpha 2c	Mus musculus	141-161
23499689-4	2013	Clonidine, moxonidine and rilmenidine inhibited the EFS-induced gastric contractions in a concentration dependent manner in WT, alpha2B- and alpha2C-adrenoceptor KO mice, whereas they had no or only weak effect in alpha2A-adrenoceptor KO mice.	Rilmenidine	26-37	adrenergic receptor, alpha 2a	Mus musculus	214-221
21947253-0	2012	Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor.	Rilmenidine	0-11	mitogen-activated protein kinase 14	Homo sapiens	47-50
21947253-0	2012	Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor.	Rilmenidine	0-11	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	107-117
21947253-3	2012	It has been reported that activation of imidazoline I-1 receptor by rilmenidine increases the expression of FXR in human hepatoma cell line, Hep G2 cell, to regulate the target genes relating to lipid metabolism; activation of FXR by rilmenidine exerts an antihyperlipidemic action.	Rilmenidine	68-79	nuclear receptor subfamily 1 group H member 4	Homo sapiens	108-111
21947253-3	2012	It has been reported that activation of imidazoline I-1 receptor by rilmenidine increases the expression of FXR in human hepatoma cell line, Hep G2 cell, to regulate the target genes relating to lipid metabolism; activation of FXR by rilmenidine exerts an antihyperlipidemic action.	Rilmenidine	68-79	nuclear receptor subfamily 1 group H member 4	Homo sapiens	227-230
21947253-3	2012	It has been reported that activation of imidazoline I-1 receptor by rilmenidine increases the expression of FXR in human hepatoma cell line, Hep G2 cell, to regulate the target genes relating to lipid metabolism; activation of FXR by rilmenidine exerts an antihyperlipidemic action.	Rilmenidine	234-245	nuclear receptor subfamily 1 group H member 4	Homo sapiens	108-111
21947253-3	2012	It has been reported that activation of imidazoline I-1 receptor by rilmenidine increases the expression of FXR in human hepatoma cell line, Hep G2 cell, to regulate the target genes relating to lipid metabolism; activation of FXR by rilmenidine exerts an antihyperlipidemic action.	Rilmenidine	234-245	nuclear receptor subfamily 1 group H member 4	Homo sapiens	227-230
21947253-8	2012	Otherwise, rilmenidine increased the phosphorylation of p38 to increase the expression of FXR.	Rilmenidine	11-22	mitogen-activated protein kinase 14	Homo sapiens	56-59
21947253-8	2012	Otherwise, rilmenidine increased the phosphorylation of p38 to increase the expression of FXR.	Rilmenidine	11-22	nuclear receptor subfamily 1 group H member 4	Homo sapiens	90-93
21947253-9	2012	Deletion of calcium ions by BAPTA-AM reversed the rilmenidine-induced p38 phosphorylation.	Rilmenidine	50-61	mitogen-activated protein kinase 14	Homo sapiens	70-73
21947253-10	2012	In conclusion, we suggest that rilmenidine activates I-1 receptor to increase intracellular calcium ions that may enhance the phosphorylation of p38 to higher the expression of FXR for improvement of hepatic steatosis in both animals and cells.	Rilmenidine	31-42	mitogen-activated protein kinase 14	Homo sapiens	145-148
21947253-10	2012	In conclusion, we suggest that rilmenidine activates I-1 receptor to increase intracellular calcium ions that may enhance the phosphorylation of p38 to higher the expression of FXR for improvement of hepatic steatosis in both animals and cells.	Rilmenidine	31-42	nuclear receptor subfamily 1 group H member 4	Homo sapiens	177-180
21484668-3	2011	Farnesoid X receptor (FXR) plays an important role in blood lipid homeostasis; however, the role of FXR in rilmenidine-induced blood lipid lowering action is still unknown.	Rilmenidine	107-118	nuclear receptor subfamily 1, group H, member 4	Mus musculus	100-103
21484668-4	2011	Thus, we administered rilmenidine, a selective agonist of I-1 R, into high fat diet-fed (HFD) mice showing hypertriglyceridemia and hypercholesterolemia.	Rilmenidine	22-33	nischarin	Mus musculus	58-63
21484668-6	2011	Pretreatment with efaroxan, at a dose sufficient to inhibit I-1 R activation, blocked the effects of rilmenidine.	Rilmenidine	101-112	nischarin	Mus musculus	60-65
21484668-7	2011	Also, in cultured HepG2 cells, rilmenidine dose-dependently induced the expression of farnesoid X receptor (FXR).	Rilmenidine	31-42	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	96-106
21484668-7	2011	Also, in cultured HepG2 cells, rilmenidine dose-dependently induced the expression of farnesoid X receptor (FXR).	Rilmenidine	31-42	nuclear receptor subfamily 1 group H member 4	Homo sapiens	108-111
21484668-8	2011	The rilmenidine-induced FXR expression and FXR-related genes were blocked by efaroxan.	Rilmenidine	4-15	nuclear receptor subfamily 1, group H, member 4	Mus musculus	24-27
21484668-8	2011	The rilmenidine-induced FXR expression and FXR-related genes were blocked by efaroxan.	Rilmenidine	4-15	nuclear receptor subfamily 1, group H, member 4	Mus musculus	43-46
20816810-8	2010	We also performed Western blot analysis to determine phosphorylation of Akt and glycogen synthase kinase 3beta, a direct Akt downstream target, following the central administration of rilmenidine.	Rilmenidine	184-195	glycogen synthase kinase 3 beta	Rattus norvegicus	80-110
20816810-8	2010	We also performed Western blot analysis to determine phosphorylation of Akt and glycogen synthase kinase 3beta, a direct Akt downstream target, following the central administration of rilmenidine.	Rilmenidine	184-195	AKT serine/threonine kinase 1	Rattus norvegicus	121-124
20816810-10	2010	Rilmenidine increased Akt and glycogen synthase kinase 3beta phosphorylation (28+-13% and 32+-13%, respectively), and this action was abolished by wortmannin.	Rilmenidine	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	22-25
20816810-10	2010	Rilmenidine increased Akt and glycogen synthase kinase 3beta phosphorylation (28+-13% and 32+-13%, respectively), and this action was abolished by wortmannin.	Rilmenidine	0-11	glycogen synthase kinase 3 beta	Rattus norvegicus	30-60
20816810-11	2010	The present results demonstrated that pertussis toxin-sensitive G protein, phosphatidylinositol 3-kinase-Akt-GSK3beta signaling pathway and endogenous nitric oxide may play a key role in antiarrhythmic effect of centrally administered rilmenidine.	Rilmenidine	235-246	AKT serine/threonine kinase 1	Rattus norvegicus	105-108
15965355-7	2005	Intra-RVLM rilmenidine decreased c-Fos expression, and these responses were abolished by efaroxan but not by SK&F 86466.	Rilmenidine	11-22	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	33-38
20190273-7	2010	This screen suggested that rilmenidine, a well tolerated, safe, centrally acting anti-hypertensive drug, could induce autophagy in cell culture via a pathway that was independent of the mammalian target of rapamycin.	Rilmenidine	27-38	mechanistic target of rapamycin kinase	Homo sapiens	186-215
20190273-9	2010	Rilmenidine administration attenuated the signs of disease in a HD mouse model and reduced levels of the mutant huntingtin fragment.	Rilmenidine	0-11	huntingtin	Mus musculus	112-122
19526313-6	2009	Similarly, clonidine and rilmenidine in the same dose range reduced the oedema formation induced by carrageenan, yohimbine and the alpha(2A)-adrenoceptor antagonist BRL-44408 (3 micromol/kg i.p.)	Rilmenidine	25-36	adrenoceptor alpha 2A	Homo sapiens	131-153
16280284-0	2005	Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension.	Rilmenidine	51-62	adiponectin, C1Q and collagen domain containing	Homo sapiens	80-91
16280284-4	2005	The aim of the study was to evaluate the effect of 6 months of antihypertensive therapy with rilmenidine on plasma adiponectin concentration in patients with essential hypertension.	Rilmenidine	93-104	adiponectin, C1Q and collagen domain containing	Homo sapiens	115-126
16280284-6	2005	RESULTS: The 6 months of treatment with rilmenidine resulted in a significant decrease of systolic (P = .007), diastolic (P = .002), and mean arterial blood pressure (P = .002), no significant change of body mass index (27.7 +/- 4.7 and 27.6 +/- 4.4 kg/m(2)), total body fat content (25.4 +/- 7.3 and 24.9 +/- 6.8 kg), and insulin sensitivity parameters (M value 6.0 +/- 2.5 and 5.8 +/- 4.3 mg/kg/min and M/plasma insulin ratio 7.4 +/- 5.0 and 6.9 +/- 4.3 mg/kg/min/mU/L).	Rilmenidine	40-51	insulin	Homo sapiens	323-330
16280284-6	2005	RESULTS: The 6 months of treatment with rilmenidine resulted in a significant decrease of systolic (P = .007), diastolic (P = .002), and mean arterial blood pressure (P = .002), no significant change of body mass index (27.7 +/- 4.7 and 27.6 +/- 4.4 kg/m(2)), total body fat content (25.4 +/- 7.3 and 24.9 +/- 6.8 kg), and insulin sensitivity parameters (M value 6.0 +/- 2.5 and 5.8 +/- 4.3 mg/kg/min and M/plasma insulin ratio 7.4 +/- 5.0 and 6.9 +/- 4.3 mg/kg/min/mU/L).	Rilmenidine	40-51	insulin	Homo sapiens	414-421
16280284-7	2005	However after 6 months of treatment with rilmenidine a significant increase in plasma adiponectin concentration (from 12.5 +/- 6.1 to 16.9 +/- 11.1; P = .0002) was observed.	Rilmenidine	41-52	adiponectin, C1Q and collagen domain containing	Homo sapiens	86-97
16280284-8	2005	CONCLUSIONS: Antihypertensive therapy with rilmenidine correlates with an increase of plasma adiponectin concentration without any significant changes of insulin sensitivity and body fat content in patients with essential hypertension.	Rilmenidine	43-54	adiponectin, C1Q and collagen domain containing	Homo sapiens	93-104
20015085-1	2010	BACKGROUND AND PURPOSE: We determined if chronic sympatho-inhibition with rilmenidine has functional significance for the kidney by altering responses of renal blood flow (RBF) and plasma renin activity (PRA) to stress and acute hypotension in rabbits with renovascular hypertension.	Rilmenidine	74-85	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	188-193
17940198-0	2008	Inhibition of nischarin expression attenuates rilmenidine-evoked hypotension and phosphorylated extracellular signal-regulated kinase 1/2 production in the rostral ventrolateral medulla of rats.	Rilmenidine	46-57	nischarin	Rattus norvegicus	14-23
16197523-11	2005	Rilmenidine (a mixed alpha2R/I1R agonist) attenuated aversion to opiate withdrawal in a dose-dependent manner.	Rilmenidine	0-11	nischarin	Rattus norvegicus	29-32
15901801-1	2005	Our previous study showed that rilmenidine, a selective I(1)-imidazoline receptor agonist, enhanced the phosphorylation of mitogen-activated protein kinase (MAPK)(p42/44), via the phosphatidylcholine-specific phospholipase C pathway in the pheochromocytoma cell line (PC12).	Rilmenidine	31-42	mitogen activated protein kinase 3	Rattus norvegicus	157-161
15901801-7	2005	An increase in RVLM MAPK(p42/44) occurred only after rilmenidine.	Rilmenidine	53-64	mitogen activated protein kinase 3	Rattus norvegicus	20-24
15579572-9	2005	The I1 agonist rilmenidine, but not the alpha2-agonist UK14304, inhibited XII output.	Rilmenidine	15-26	nischarin	Rattus norvegicus	4-6
11721891-2	2001	Rilmenidine is as effective in monotherapy as all other first-line classes of drugs, including diuretics, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and calcium antagonists.	Rilmenidine	0-11	angiotensin I converting enzyme	Homo sapiens	152-155
15028595-4	2003	Rilmenidine and moxonidine acutely raised glucose and lowered insulin, thereby further worsening glucose tolerance.	Rilmenidine	0-11	insulin	Homo sapiens	62-69
15834464-10	2005	More clinical trials are needed for the centrally acting antihypertensives (clonidine, rilmenidine) in obese hypertensive patients, as they inhibit the sympathetic nervous and renin--angiotensin systems, which are overactive in this population.	Rilmenidine	87-98	renin	Homo sapiens	176-181
15506067-5	2004	DESIGN AND METHODS: The HERA study (Hyperium Effect on the sympathetic Reflex activation and Adrenaline) is a randomised, double-blind, 6-week cross-over trial, with a 1-week placebo run-in period, two 2-week active treatment intervals (rilmenidine 1 mg bid, placebo) and intervening one week placebo wash-out.	Rilmenidine	36-44	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	24-28
12425202-9	2002	RESULTS: Rilmenidine treatment resulted in normalisation of blood pressure (BP) or significant (decrease of SBP/DBP = 20/10 mm Hg) blood pressure decrease in 69%, 22% of subjects, respectively.	Rilmenidine	9-20	selenium binding protein 1	Homo sapiens	108-111
11274989-4	2001	The Western blotting analysis showed that rilmenidine (10 microM) produced a time-dependent activation of p42(mapk) and p44(mapk) that reached its maximum at 15 min and returned to control levels after 30 min.	Rilmenidine	42-53	mitogen activated protein kinase 1	Rattus norvegicus	110-114
11274989-4	2001	The Western blotting analysis showed that rilmenidine (10 microM) produced a time-dependent activation of p42(mapk) and p44(mapk) that reached its maximum at 15 min and returned to control levels after 30 min.	Rilmenidine	42-53	mitogen activated protein kinase 3	Rattus norvegicus	120-123
11274989-4	2001	The Western blotting analysis showed that rilmenidine (10 microM) produced a time-dependent activation of p42(mapk) and p44(mapk) that reached its maximum at 15 min and returned to control levels after 30 min.	Rilmenidine	42-53	mitogen activated protein kinase 1	Rattus norvegicus	124-128
10882231-9	2000	In a host-cell-specific manner, transfection of IRAS cDNA into Chinese hamster ovary cells led to high-affinity I1 binding sites by criteria of nanomolar affinity for moxonidine and rilmenidine.	Rilmenidine	182-193	nischarin	Homo sapiens	48-52
11057441-11	2000	Plasminogen activator inhibitor type 1 (PAI-1) antigen and PAI-1 activity were only decreased in the rilmenidine group (not statistically significant).	Rilmenidine	101-112	serpin family E member 1	Homo sapiens	0-38
11057441-11	2000	Plasminogen activator inhibitor type 1 (PAI-1) antigen and PAI-1 activity were only decreased in the rilmenidine group (not statistically significant).	Rilmenidine	101-112	serpin family E member 1	Homo sapiens	40-45
11057441-11	2000	Plasminogen activator inhibitor type 1 (PAI-1) antigen and PAI-1 activity were only decreased in the rilmenidine group (not statistically significant).	Rilmenidine	101-112	serpin family E member 1	Homo sapiens	59-64
9851560-0	1998	[3H]Rilmenidine-labelled imidazoline-receptor binding sites co-localize with [3H]2-(benzofuranyl)-2-imidazoline-labelled imidazoline-receptor binding sites and monoamine oxidase-B in rabbit, but not rat, kidney.	Rilmenidine	4-15	amine oxidase [flavin-containing] B	Oryctolagus cuniculus	160-179
9747912-1	1998	OBJECTIVE: To assess the effect of 1-year treatment with rilmenidine, an oxazoline compound that exerts its antihypertensive effects through binding to imidazoline receptors in the brainstem, on left ventricular hypertrophy (LVH) secondary to essential, mild-to-moderate hypertension [supine diastolic blood pressure (DBP)95-115 mmHg].	Rilmenidine	57-68	D-box binding PAR bZIP transcription factor	Homo sapiens	318-321
9851561-5	1998	Under identical buffer conditions, the Bmax of [3H]rilmenidine-labelled I-RBS (1.45+/-0.14 pmol/mg protein) was considerably lower than those of MAO-A (13.10+/-0.15 pmol/mg) and MAO-B (10.35+/-0.50 pmol/mg) sites.	Rilmenidine	51-62	monoamine oxidase B	Rattus norvegicus	178-183
9326738-0	1997	Effect of rilmenidine injection into the paraventricular nucleus of the hypothalamus on the water intake induced by application of angiotensin II to the subfornical organ.	Rilmenidine	10-21	angiotensinogen	Homo sapiens	131-145
9638593-3	1998	Based on the results we may conclude that clonidine associated with rilmenidine was able to block the hypertensive response to ANG II.	Rilmenidine	68-79	angiotensinogen	Rattus norvegicus	127-133
9638593-6	1998	The injection of rilmenidine (30 micrograms/kg/1 microL), an imidazoline agonist agent injected into PVN before ANG II injection into SFO, blocked the pressor effect of ANG II (5 +/- 2 mmHg).	Rilmenidine	17-28	angiotensinogen	Rattus norvegicus	112-118
9638593-6	1998	The injection of rilmenidine (30 micrograms/kg/1 microL), an imidazoline agonist agent injected into PVN before ANG II injection into SFO, blocked the pressor effect of ANG II (5 +/- 2 mmHg).	Rilmenidine	17-28	angiotensinogen	Rattus norvegicus	169-175
9638593-12	1998	In summary, the present study demonstrated that rilmenidine decreases the hypertensive effect of ANG II, with more potency than clonidine, even when injected into 3rdV or PVN.	Rilmenidine	48-59	angiotensinogen	Rattus norvegicus	97-103
9033699-5	1996	No difference between the groups was demonstrated during the 8 weeks of treatment for the course of blood pressure: SBP and DBP decreased by 20.5 and 13.9 mmHg, respectively, in the rilmenidine group and by 21.3 and 13.1 mmHg in the captopril group (no significant difference: NS).	Rilmenidine	182-193	selenium binding protein 1	Homo sapiens	116-119
9033699-5	1996	No difference between the groups was demonstrated during the 8 weeks of treatment for the course of blood pressure: SBP and DBP decreased by 20.5 and 13.9 mmHg, respectively, in the rilmenidine group and by 21.3 and 13.1 mmHg in the captopril group (no significant difference: NS).	Rilmenidine	182-193	D-box binding PAR bZIP transcription factor	Homo sapiens	124-127